SUNNYVALE, CA, Oct. 1 /CNW/ - MDS Analytical Technologies, a leader in
innovative solutions for drug discovery and life sciences research, announced
today the launch of a significant advance in high speed imaging technologies
from its Molecular Devices business with the release of the MetaMorph(R) ICS
(Integrated Confocal System), in partnership with VisiTech International, a
manufacturer of confocal hardware. This turnkey, confocal microscope is the
first of its kind in the imaging industry. It has the capability to obtain
high resolution images in multiple dimensions to support researchers in their
exploration of live cell and functional imaging without the limitations
inherent in other high-speed imaging technologies.
This unique microscope combines the Molecular Devices' MetaMorph
software, which is the industry standard automation and image analysis
package, with the VT-Infinity(3)(TM) 2D-array laser confocal scanner from
VisiTech International. This combination is designed to meet the growing
demand for imaging rapid changes within cells and then analyzing these changes
in multiple dimensions.
The microscope has matched micro-lens and pinhole arrays to achieve
optimum performance and a single, double-sided galvanometer mirror to scan the
sample, de-scan the fluorescent light returned from the sample, and re-scan
that fluorescent light into the camera to create multi-dimensional, confocal
images in real-time. This capability is especially useful in such areas as
cardiac research. For example, after a heart attack, researchers want to know
how the cardiac muscle contracts to determine if there is damage to the
muscle. Using calcium imaging with the MetaMorph ICS, the reaction of cardiac
muscle cells can be analyzed in real-time, giving researchers important clues
as to how the cardiac muscle works.
This new microscope can be used in multiple imaging applications,
including protein localization, protein-protein interactions, gene expression,
intra-cellular ion waves, calcium puffs and sparks, FRET, co-localization,
tissue section morphology and 3D reconstruction.
"We are very excited to introduce this innovative microscope, a first of
its kind in the imaging industry," said Andy Boorn, President of MDS
Analytical Technologies. "We've combined the speed, resolution, and
sensitivity of the multi-dimensional, confocal imaging technology with the
methods and applications in our MetaMorph software to produce a powerful new
solution for researchers to advance their analysis with live cell and
Professor Dr. Peter Lipp, chair of the Institute for Molecular Cell
Biology at the University of the Saarland in Homburg, Germany, commented, "In
our research lab, we use the VT-Infinity(3) scanner. This scanner represents
an entirely new level in multi-beam confocal technology, offering greater
flexibility and ultra-high-speed acquisition. It was an excellent choice to
use as the scanning component in the new MetaMorph ICS."
The new MetaMorph ICS microscope will be presented at the American
Society for Cell Biology Annual Meeting, December 1-5, 2007 in Washington, DC,
at MDS Analytical Technologies' Molecular Devices booth No.1203.
About MDS Inc.
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that
provides market-leading products and services that our customers need for the
development of drugs and diagnosis and treatment of disease. We are a leading
global provider of pharmaceutical contract research, medical isotopes for
molecular imaging, radiotherapeutics, and analytical instruments. MDS has more
than 6,200 highly skilled people in 28 countries. Find out more at
www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
About MDS Analytical Technologies
MDS Analytical Technologies is a newly established MDS Inc. business unit
and is a world-class organization comprised of two main lines of business. The
Sciex product portfolio offers proven market leadership in mass spectrometry
through its joint ventures with two of the world's leading analytical
instrumentation and life sciences companies, Applied Biosystems, a business of
the Applera Corporation and PerkinElmer Inc. The Molecular Devices product
portfolio is the gold standard in high-performance bioanalytical measurement
systems that accelerate and improve drug discovery and other life sciences
research. Find out more at www.moleculardevices.com or www.mdssciex.com.
For further information:
For further information: Media: Cheri Salazar, Director, Marketing
Communications, Molecular Devices, now part of MDS Analytical Technologies,
(408) 548-6316, email@example.com; Investors: Sharon Mathers, Senior
Vice-President, Investor Relations and External Communications, MDS Inc.,
(416) 675-6777 x 34721, firstname.lastname@example.org